CLAIMS

What is claimed is:

~~1. A method of supporting resistance to a disease or condition in a human comprising administering to the human a nutritional composition comprising:~~

~~a) a fat or lipid source;~~

~~b) a protein source; and~~

~~c) lactoferrin produced by a non-human source, wherein the lactoferrin has at least 48% homology with the amino acid sequence AVGEQELRKCNQWSGL at the HLf (349-364) fragment.~~

~~2. The method of claim 1 where the disease or condition is one caused by at least one pathogen selected from the group consisting Enterotoxigenic E. coli, Enteropathogenic E. coli, Haemophilus influenza, Shigatoxin producing E. coli, Enteroaggregative E. coli, Salmonella ser. Typhimurium, Shigella flexneri, Rotavirus, Norovirus, Respiratory syncytial virus, Adenovirus, and combinations thereof.~~

~~3~~2. The use~~method~~ according to claim 1, wherein the ~~diease or condition~~disease is viral respiratory tract infection.

~~4~~3. The use~~method~~ according to claim 1, wherein the human is an infant or a child.

~~5~~4. The use~~method~~ according to claim 1, wherein the fat or lipid source is present at a level of ~~about~~ 3 g/100 kcal to ~~about~~ 7 g/100 kcal and the protein source is present at a level of ~~about~~ 1 g/100 kcal to ~~about~~ 5 g/100 kcal.

~~6~~5. The use~~method~~ according to claim 1, wherein the lactoferrin is present at a level of at least ~~about~~ 10 mg/100 kcal.

~~7~~6. The use~~method~~ according to claim ~~5~~6, wherein the lactoferrin is present at a level of ~~about~~ 70 mg/100 kcal to ~~about~~ 220 mg/100 kcal.

~~8~~7. The use~~method~~ according to claim 1, wherein the lactoferrin is selected from the group consisting of non-human lactoferrin, human lactoferrin produced by a genetically modified organism, and combinations thereof.

~~9. The method according to claim 1, wherein the lactoferrin is stable and remains active under conditions under which human lactoferrin become unstable or inactive.~~

~~10~~8. The use~~method~~ according to claim ~~1~~9, wherein the nutritional composition has been subject to pasteurization conditions.

~~11~~9. The use~~method~~ according to claim 1, wherein the nutritional composition further comprises a prebiotic composition comprising a compound selected from the group consisting of galactooligosaccharide, polydextrose, and combinations thereof.

~~12~~10. The use~~method~~ according to claim 1, wherein the nutritional composition comprises ~~about~~ 0.5 mg/100 kcal to ~~about~~ 5 mg/100 kcal of iron, including iron bound to lactoferrin.

~~13~~11. The use~~method~~ according to claim 1, wherein the lactoferrin has at least 65% homology with the amino acid sequence AVGEQELRKCNQWSGL at the HLf (349-364) fragment.

~~14~~12. The use~~method~~ according to claim 1, wherein the human has the disease ~~or condition~~ when the nutritional composition is to be administered.

~~15~~13. The use~~method~~ according to claim 1, wherein the nutritional composition is to be administered prophylactically and the human does not have the disease ~~or condition~~ when the nutritional composition is to be administered.